Company news

Prelude Therapeutics Incorporated news in 2024

Prelude Therapeutics Incorporated's news releases, calls and decks from 2024, newest first.

View company

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

December 10, 2024

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

November 26, 2024

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 5, 2024

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

October 23, 2024

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

October 8, 2024

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

September 12, 2024

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

September 8, 2024

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 11, 2024

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

July 8, 2024

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

May 8, 2024

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

April 8, 2024

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

March 4, 2024

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

February 28, 2024

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

February 14, 2024

Decks in 2024